Highest-materiality recent filing
Agilent closes $600M offering of 4.900% Senior Notes due 2032
$600M aggregate principal of 4.900% Senior Notes due Jan 15, 2032, issued at 99.968%.
Agilent Q2 FY26 revenue $1.83B (+10% YoY), non-GAAP EPS $1.49 (+14%), raises FY26 guidance
Revenue $1.83B, +10% reported (+6.3% core); GAAP EPS $1.20 (+60%), non-GAAP EPS $1.49 (+14%).
Agilent appoints Michael Buckner as Chief Legal Officer, replacing Bret DiMarco
Bret DiMarco resigned as Chief Legal Officer and Secretary effective May 4, 2026; will serve as Special Advisor through Dec 1, 2026.
Agilent CLO Bret DiMarco to resign, serve as Special Advisor through Dec 2026
DiMarco resigns as SVP, Chief Legal Officer and Secretary upon new CLO start or Sept 30, 2026.
Agilent CLO Bret DiMarco to step down; will serve as Special Advisor until Dec 1, 2026
Resigns as SVP, CLO & Secretary upon start of new CLO or Sept 30, 2026, whichever earlier.
Agilent shareholders approve board declassification, elect four directors at annual meeting
Shareholders approved declassification of board over three years: 227.3M for, 0.4M against (Proposal 4).
Agilent VP, Corporate Controller and PAO to retire in January 2027
Rodney Gonsalves to retire as VP, Corporate Controller and Principal Accounting Officer in January 2027; exact date TBD.
Agilent Q1 FY2026 revenue $1.80B (+7% YoY), non-GAAP EPS $1.36 (+4%), raises FY guidance
Q1 revenue $1.80B, up 7% reported and 4.4% core YoY; GAAP EPS $1.07 (down 4%), non-GAAP EPS $1.36 (up 4%).
Agilent Q4 revenue $1.86B beats guidance; non-GAAP EPS $1.59 up 9%; initiates FY26 outlook $7.3-7.4B
Q4 revenue $1.86B, +9.4% reported/+7.2% core; GAAP EPS $1.53 (+25%); non-GAAP EPS $1.59 (+9%).
Agilent appoints Adam Elinoff as CFO effective Nov 17; $700k base salary plus equity
Adam S. Elinoff named CFO effective Nov 17, 2025, succeeding interim CFO Rodney Gonsalves.
Agilent beats Q3 with $1.74B revenue, raises FY2025 revenue outlook
Q3 revenue $1.74B, +10.1% reported / +6.1% core, above guidance; GAAP EPS $1.18 (+22%), Non-GAAP EPS $1.37 (+4%).
Agilent discloses interim CFO compensation: $8,654 bi-weekly stipend + $1M RSU grant
Rodeny Gonsalves interim CFO receives $8,654 bi-weekly stipend effective July 31, 2025, during service.
Agilent CFO Bob McMahon to resign effective July 31; Rodney Gonsalves named interim CFO
Bob McMahon, SVP & CFO, resigns effective July 31, 2025; departure for personal/family reasons, not related to accounting or operations.
Agilent Q2 revenue up 6% to $1.67B; Non-GAAP EPS $1.31, +7% YoY; raises FY outlook
Q2 revenue $1.67B (+6% reported, +5.3% core YoY); GAAP EPS $0.75 (-29%), Non-GAAP EPS $1.31 (+7%).
Agilent appoints AstraZeneca CEO Pascal Soriot and Judy Brown to board; Kunz retires.
Pascal Soriot (AstraZeneca CEO) and Judy Gawlik Brown (Downtown Advisory) appointed effective May 21, 2025.
Agilent SVP & President of Order Fulfillment & Supply Chain resigns effective June 1
Henrick Ancher-Jensen notified his resignation on April 28, 2025, effective June 1, 2025.
Agilent board member Heidi Kunz resigns effective May 21, 2025
Heidi Kunz notified Board on March 27, 2025; resignation effective May 21, 2025.
Agilent stockholders elect two directors, approve compensation, auditor, and governance changes
Otis W. Brawley, M.D. and Mikael Dolsten, M.D., Ph.D. elected to three-year terms with >85% of votes cast.
Former Diagnostics & Genomics merged with LC/MS platforms into Life Sciences and Diagnostics Markets segment.
Agilent Q1 revenue $1.68B, non-GAAP EPS $1.31, beats expectations; maintains FY outlook
Revenue $1.68B, up 1.4% reported and 1.2% core YoY; GAAP EPS $1.11, down 6%; non-GAAP EPS $1.31, up 2%.
Agilent reorganizes into three reportable segments: LSD, Applied, CrossLab
New segments: Life Sciences & Diagnostics Markets, Applied Markets, Agilent CrossLab, effective FY2025.
Agilent reorganizes into three business groups; names new presidents for LDG and AMG
New structure: Life Sciences & Diagnostics Markets Group (38% rev), Applied Markets Group (20%), Agilent CrossLab Group (42%).
Agilent Q4 revenue flat YoY; Non-GAAP EPS +6%; guides FY25 rev growth 4-5%
Q4 revenue $1.70B (flat YoY reported +0.8%, core -0.3%); GAAP EPS $1.22 (-25%), Non-GAAP EPS $1.46 (+6%).
Agilent closes $1.2B senior notes offering to finance BioVectra acquisition
Issued $600M 4.200% notes due 2027 and $600M 4.750% notes due 2034 at 99.866% and 99.638% of par, respectively.
Agilent prices $1.2B senior notes in two tranches: $600M 4.200% due 2027, $600M 4.750% due 2034
$600M 4.200% senior notes due 2027; $600M 4.750% senior notes due 2034.
Agilent recasts segment financials moving cell analysis to diagnostics and genomics
Move of cell analysis from life sciences/applied markets to diagnostics/genomics segment effective Q1 FY2024.
Agilent Q3 revenue $1.58B beats guidance; GAAP EPS $0.97 (+155%); raises FY midpoint
Q3 revenue $1.58B (-5.6% reported, -4.4% core); GAAP EPS $0.97 (+155% YoY); non-GAAP EPS $1.32 (-8% YoY).
Agilent Q2 revenue down 8.4% YoY, cuts full-year outlook; authorizes $2B buyback
Q2 revenue $1.57B (-8.4% reported); GAAP EPS $1.05 (+3% YoY), non-GAAP EPS $1.22 (-4% YoY).
Agilent discloses CEO Padraig McDonnell's compensation: $1.075M base, $3.3M equity
Annual base salary of $1,075,000; target performance bonus of 125% effective June 1, 2024.
Director Hans E. Bishop steps down from Agilent board; board size reduced to 10
Hans E. Bishop resigned from Agilent board effective May 23, 2024, after serving since 2017.
Padraig McDonnell becomes Agilent CEO as Mike McMullen retires May 1, 2024
Michael McMullen retired as President, CEO, and board member effective May 1, 2024; will serve as senior adviser through Oct. 31.
Mala Anand, Koh Boon Hwee, Michael McMullen, and Daniel Podolsky elected as directors for three-year terms.
Agilent Q1 FY2024 revenue $1.66B (-5.6% YoY), EPS $1.18 GAAP/$1.29 non-GAAP; guides Q2 down
Revenue $1.66B, down 5.6% reported and 6.4% core YoY; GAAP EPS $1.18, non-GAAP EPS $1.29.
Agilent CEO Mike McMullen to retire May 1; Padraig McDonnell named CEO-elect and COO
Mike McMullen to retire as President and CEO effective May 1, 2024, then serve as senior advisor until Oct 31.
Agilent moves Cell Analysis Div. to D&G segment; recasts FY21-23 segment data
Cell Analysis Division moved from LSAG to Diagnostics & Genomics Group (DGG) effective Q1 FY24.
Agilent moves Cell Analysis Division into Diagnostics and Genomics Group
Cell Analysis Division moved from LSAG to DGG; effective Q1 fiscal 2024.
Agilent Q4 revenue $1.69B (-8.7% reported), non-GAAP EPS $1.38; FY24 guidance cautious
Q4 revenue $1.69B, down 8.7% reported and 9.7% core YoY; GAAP EPS $1.62 (+32%), non-GAAP EPS $1.38 (-10%).
Agilent's DGG President Sam Raha to resign effective Dec 8, 2023
Sam Raha resigns as Senior Vice President and President of Diagnostics and Genomics Group (DGG).
Agilent names Philip Binns LSAG president after Jacob Thaysen departs
Jacob Thaysen resigned as SVP and president of Life Sciences and Applied Markets Group (LSAG), effective Sept. 5, 2023.
Agilent Q3 revenue down 2.7% YoY to $1.67B; GAAP EPS $0.38; lowers FY2023 guidance
Reported revenue $1.67B, down 2.7% YoY; core revenue down 2.3%.
Agilent enters $1.5B unsecured revolving credit facility, matures 2028
Credit Agreement with BNP Paribas provides $1.5B five-year unsecured facility, maturing June 7, 2028.
GAAP EPS $1.02, up 12% YoY; non-GAAP EPS $1.27, up 12% YoY.
Agilent adopts bylaw amendment allowing stockholders with 20%+ stake to call special meetings
Board approved amendment to Bylaws on May 17, 2023.
Agilent shareholders approve all five proposals at 2023 annual meeting
Elected Heidi Kunz, Susan Rataj, George Scangos, Dow Wilson as directors, each with >199M votes for.
Agilent Q1 revenue $1.76B (up 10% core); raises FY23 EPS guidance to $5.65-$5.70
GAAP EPS $1.19 (up 28% YoY); non-GAAP EPS $1.37 (up 13% YoY).
Agilent authorizes $2 billion share repurchase program starting March 1, 2023
Board approved new stock repurchase program of up to $2 billion of common stock.
Agilent Q4 revenue $1.85B, non-GAAP EPS $1.53; guides FY2023 revenue $6.90-7.00B
Q4 revenue $1.85B, +11% reported (+17% core); GAAP EPS $1.23, non-GAAP EPS $1.53 (+26% YoY).
Agilent Q3 FY2022: EPS beat; guides FY rev $6.75-6.775B, non-GAAP EPS $5.06-5.08
Revenue $1.72B (+8% reported, +13% core); GAAP EPS $1.10 (+28% YoY); non-GAAP EPS $1.34 (+22% YoY).
Agilent Q2 revenue $1.61B (+7% core), non-GAAP EPS $1.13; raises FY core growth to 8-9%
GAAP net income $274M ($0.91 EPS) vs $216M ($0.70) YoY; non-GAAP $340M ($1.13 EPS) vs $299M ($0.97), up 16%.
Agilent enters $600M term loan to refinance 3.875% senior notes due 2023
Delayed draw term loan facility of $600M, maturing April 15, 2025.
As previously disclosed, on March 5, 2026, Rodney Gonsalves, informed the Company that he would retire from his position as the Company’s Vice President, Corporate Controller and Principal Accounting Officer, the exact date to be determined at a later time.
On May 20, 2026, the Company appointed Tim Downs as the new Vice President, Chief Accounting Officer of the Company and as principal accounting officer of the Company, effective as of the first business day following the Company’s filing of the quarterly report on Form 10-Q for the quarter ended April 30, 2026 (the “Start Date”).
On May 4, 2026, the Company appointed Michael Buckner as the new Chief Legal Officer and, as a result, effective on such date, Mr. DiMarco resigned from his positions as Senior Vice President, Chief Legal Officer and Secretary of the Company.
On May 4, 2026, the Company appointed Michael Buckner as the new Chief Legal Officer
Mr. Soriot was appointed to serve in the class of directors that will stand for re-election at the 2028 Annual Meeting of Stockholders.
Ms. Brown was appointed to serve in the class of directors that will stand for re-election at the 2026 Annual Meeting of Stockholders.
On April 28, 2025, Henrick Ancher-Jensen, Senior Vice President, Agilent President, Order Fulfillment and Supply Chain of Agilent Technologies, Inc. (the “Company”), notified the Company of his decision to resign from his position effective as of June 1, 2025, to pursue another opportunity.
On March 27, 2025, Heidi Kunz, a member of the Board of Directors (the “Board”) of Agilent Technologies, Inc. (the “Company”), a member of the Compensation Committee of the Board (the “Compensation Committee”), and a member of the Nominating/Corporate Governance Committee of the Board (together with the Compensation Committee, the “Committees”), notified the Chairman of the Board of her decision to resign from the Board and the Committees, effective as of May 21, 2025.
On May 22, 2024, Hans E. Bishop notified the board of directors (the “ Board ”) of Agilent Technologies, Inc. (the “ Company ”) of his intention to step down as a member of the Company’s Board, effective as of May 23, 2024.
The Board appointed Padraig McDonnell as CEO of the Company and as a member of the Company’s Board.
On May 1, 2024, Mr. McMullen retired as President and CEO of the Company and as a member of the Company’s Board.
the Board appointed Padraig McDonnell, age 52 and a Senior Vice President of the Company, as Chief Operating Officer (“COO”) and CEO-elect.
Max materiality 0.80 · Median 0.60 · Most common event earnings